Premature conclusions on HPV-only testing - Authors' reply

The Lancet Oncology

Volumn 12, Issue 11, 2011, Pages 993-

  Katki, Hormuzd A ^a   Kinney, Walter K ^b   Fetterman, Barbara ^c   Lorey, Thomas ^c   Poitras, Nancy E ^c   Cheung, Li ^d   Demuth, Franklin ^d   Schiffman, Mark ^a   Wacholder, Sholom ^a   Castle, Philip E ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e American Society for Clinical Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TEST; LETTER; PAPANICOLAOU TEST; PATIENT REFERRAL; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIRUS DIAGNOSIS; WART VIRUS;

EID: 80053393661     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70240-6     Document Type: Letter

References (2)

1. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12:663-672.
2. The Bethesda System for reporting cervical cytology 2004, Springer-Verlag, New York, NY. 2nd edn. D. Solomon, R. Nayar (Eds.).